The latest price target for Context Therapeutics (NASDAQ:CNTX) was reported by HC Wainwright & Co. on September 16, 2024. The analyst firm set a price target for $6.00 expecting CNTX to rise to within 12 months (a possible 165.49% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Context Therapeutics (NASDAQ:CNTX) was provided by HC Wainwright & Co., and Context Therapeutics reiterated their buy rating.

The last upgrade for Context Therapeutics Inc happened on November 1, 2023 when HC Wainwright & Co. raised their price target to $5. HC Wainwright & Co. previously had a neutral for Context Therapeutics Inc.

The last downgrade for Context Therapeutics Inc happened on March 23, 2023 when HC Wainwright & Co. changed their price target from N/A to N/A for Context Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Context Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Context Therapeutics was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest Context Therapeutics (CNTX) rating was a reiterated with a price target of $6.00 to $6.00. The current price Context Therapeutics (CNTX) is trading at is $2.26, which is out of the analyst’s predicted range.